To report a case of posterior uveitis with retinal neovascularization in a patient with Behçet disease treated with infliximab.
Methods
A 50-year-old man with a history of recurrent relapses of ocular inflammation despite immunosuppressive therapy developed retinal neovascularization near the optic disk. The patient was treated with infliximab and followed up for 12 months.
Results
Retinal neovascularization regressed 8 months after the first anti–tumor necrosis factor (TNF) treatment and with six infusions of infliximab. The ocular inflammation resolved almost completely.
Conclusions
The result suggests that anti-TNF therapy may be effective in the treatment of retinal neovascularization caused by panuveitis in Behçet disease.
SfikakisP.P., TheossidiadisP.G., KatsiariC.G.Effect of infliximab on sight-threatening panuveitis in Behçet's disease [letter]. Lancet2001; 358: 295–6.
2.
Munoz-FernandezS., HidalgoV., Fernandez-MelonJ.Effect of infliximab on threatening panuveitis in Behçet's disease [letter]. Lancet2001; 358: 1644.
3.
JosephA., RajD., DuaH.S.Infliximab in the treatment of refractory posterior uveitis. Ophthalmology2003; 110: 1449–53.
4.
TrioloG., VadalaM., Accardo-PalumboA.Anti-tumor necrosis factor antibody treatment for ocular Behçet's disease. Ann Rheum Dis2002; 61: 560–1.
5.
MainiR., St ClairE.W., BreedveldF.Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet1999; 354: 1932–9.
6.
KimuraS.J., ThygesonP., HoganM.J.Signs and symptoms of uveitis. 1. Anterior uveitis. Am J Ophthalmol1959; 47: 155–70.
7.
NussenblattR.B., PalestineA.G., ChanC.C.Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology1985; 92: 467–71.
